Regencell Bioscience (NASDAQ:RGC) Stock Price Down 11.4% – Should You Sell?

Regencell Bioscience Holdings Limited (NASDAQ:RGC)’s stock price was down 11.4% during trading on Friday. The company traded as low as $8.42 and last traded at $8.6910. Approximately 150,049 shares traded hands during mid-day trading, a decline of 50% from the average daily volume of 297,218 shares. The stock had previously closed at $9.81.

Wall Street Analysts Forecast Growth

A number of equities analysts recently commented on the stock. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Regencell Bioscience in a research note on Monday, September 21st. Wall Street Zen lowered Regencell Bioscience from a “hold” rating to a “sell” rating in a research report on Saturday, July 18th. One equities research analyst has rated the stock with a Sell rating. According to MarketBeat.com, Regencell Bioscience currently has a consensus rating of “Sell”.

Regencell Bioscience Stock Down 14.7%

The business has a 50 day moving average price of $6.66 and a 200 day moving average price of $13.54.

Regencell Bioscience (NASDAQ:RGC) last posted its earnings results on Wednesday, October 7th. The company reported ($0.01) EPS for the quarter.

Institutional Trading of Regencell Bioscience

An institutional investor recently raised its position in Regencell Bioscience stock. Bank of America Corp DE increased its position in shares of Regencell Bioscience Holdings Limited (NASDAQ:RGC) by 59,113.8% in the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 17,172 shares of the company’s stock after purchasing an additional 17,143 shares during the period. Bank of America Corp DE’s holdings in Regencell Bioscience were worth $437,000 at the end of the most recent quarter. Institutional investors and hedge funds own 0.13% of the company’s stock.

About Regencell Bioscience

Regencell Bioscience Holdings Limited is a Hong Kong-based biotechnology company focused on developing traditional Chinese medicine (TCM) formulations for neurological and neurocognitive disorders. Its research has primarily targeted attention deficit hyperactivity disorder (ADHD) and autism spectrum disorder (ASD), conditions for which the company is exploring TCM-based therapeutic approaches.

The company’s development activities center on proprietary herbal formulations and related treatment protocols.